Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme Is Ready For FDA: Geoff McDonough Explains What The Firm Is Doing To Overcome Its Problems

Executive Summary

As summer turns to fall, Genzyme is trying to place the viral contamination problems at its Allston Landing, Mass., plant in the rear-view mirror. Both Cerezyme and Fabrazyme are back in production after a July shutdown that caused shortages of the two drugs. Cerezyme is the only approved therapy for Gaucher disease, while Fabrazyme is the only U.S.-approved drug for Fabry disease.

You may also be interested in...

Genzyme Says Cerezyme Sales Fell 70%, But Allston Plant Production Is On Track

Troubled by viral contamination problems at its enzyme-replacement therapy manufacturing site, Genzyme maintains full-scale production will resume by first-quarter 2010.

FDA Inspection Items For Genzyme's Allston Plant Appear Minor

Letter specifying need for re-inspection cites equipment maintenance concerns, review of viral contamination remediation.

Continued Genzyme Problems Offer Gaucher Opportunity To Competitors

Genzyme's Allston Landing, Mass., plant - currently the only facility that produces its Cerezyme and Fabrazyme drugs - resumed working at full capacity on Aug. 28. But it seems the big biotech's manu-facturing woes are far from over: a mid-August visit by the European Medicines Agency found deficiencies, and a critical FDA inspection is still to come

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts